Earnings

NovoCure Raises FY2026 Sales Guidance from $690.000M-$710.000M to $710.000M-$725.000M vs $708.743M Est

Jul 23, 2026 · 07:01 AM ET· updated 2h ago

NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $690.000 million-$710.000 million to $710.000 million-$725.000 million vs $708.743 million estimate.

Why It Matters

NovoCure expects to make more money next year than it thought before, raising its sales forecast. When a company raises its outlook, it usually means business is going better than expected, which is something to notice when watching how the company is doing.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

NVCR20.16

+4.59 (+29.50%)

MMM170.07

-0.69 (-0.40%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.